Microclimate monitoring in the Carcer Tullianum: temporal and spatial correlation and gradients evidenced by multivariate analysis; first campaign

Too often microclimate studies in the field of cultural heritage are published without any or scarce information on sampling design, sensors (type, number, position) and instrument validation. Lacking of this fundamental information does not allow an open discussion in the scientific community. This work aims to be an invitation for a different approach

Need for Cardiovascular Risk Reduction in Persons With Serious Mental Illness: Design of a Comprehensive Intervention

Persons with serious mental illness (SMI) comprise a high-risk group for cardiovascular disease (CVD)-related mortality with rates at least twice those of the overall US. Potentially modifiable CVD risk behaviors (tobacco smoking, obesity, physical inactivity, unhealthy diet) and risk factors (hypertension, diabetes, dyslipidemia) are all markedly elevated in persons with SMI. Evaluations of programs implementing integrated medical care into specialty mental health settings have not shown meaningful effects on CVD risk factor reduction. Rigorously tested, innovative interventions are needed to address the large burden of CVD risk in populations with SMI. In this article, we describe the design of a comprehensive 18-month intervention to decrease CVD risk that we are studying in a randomized clinical trial in a community mental health organization with psychiatric rehabilitation programs. The individual-level intervention incorporated health behavior coaching and care coordination/care management to address all seven CVD risk behaviors and risk factors, and is delivered by a health coach and nurse. If successful, the intervention could be adopted within current integrated care models and significantly improve the physical health of persons with SMI

Randomized trial of achieving healthy lifestyles in psychiatric rehabilitation: the ACHIEVE trial

<p>Abstract</p> <p>Background</p> <p>Overweight and obesity are highly prevalent among persons with serious mental illness. These conditions likely contribute to premature cardiovascular disease and a 20 to 30 percent shortened life expectancy in this vulnerable population. Persons with serious mental illness need effective, appropriately tailored behavioral interventions to achieve and maintain weight loss. Psychiatric rehabilitation day programs provide logical intervention settings because mental health consumers often attend regularly and exercise can take place on-site. This paper describes the Randomized Trial of Achieving Healthy Lifestyles in Psychiatric Rehabilitation (ACHIEVE). The goal of the study is to determine the effectiveness of a behavioral weight loss intervention among persons with serious mental illness that attend psychiatric rehabilitation programs. Participants randomized to the intervention arm of the study are hypothesized to have greater weight loss than the control group.</p> <p>Methods/Design</p> <p>A targeted 320 men and women with serious mental illness and overweight or obesity (body mass index ≥ 25.0 kg/m²) will be recruited from 10 psychiatric rehabilitation programs across Maryland. The core design is a randomized, two-arm, parallel, multi-site clinical trial to compare the effectiveness of an 18-month behavioral weight loss intervention to usual care. Active intervention participants receive weight management sessions and physical activity classes on-site led by study interventionists. The intervention incorporates cognitive adaptations for persons with serious mental illness attending psychiatric rehabilitation programs. The initial intensive intervention period is six months, followed by a twelve-month maintenance period in which trained rehabilitation program staff assume responsibility for delivering parts of the intervention. Primary outcomes are weight loss at six and 18 months.</p> <p>Discussion</p> <p>Evidence-based approaches to the high burden of obesity and cardiovascular disease risk in person with serious mental illness are urgently needed. The ACHIEVE Trial is tailored to persons with serious mental illness in community settings. This multi-site randomized clinical trial will provide a rigorous evaluation of a practical behavioral intervention designed to accomplish and sustain weight loss in persons with serious mental illness.</p> <p>Trial Registration</p> <p>Clinical Trials.gov NCT00902694</p

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Sansepolcro (AR). Trebbio

Relazione sulla campagna di scavi archeologici condotta nel 2008 nell'insediamento dell'età del ferro (VIII-VI sec. .C.) di Trebbio di Sansepolcro. Nel sito, ubicato sulla riva orientale del Tevere e pertinente a una comunità umbra, vi sono evidenze di produzione ceramica su ampia scala e di scambi di beni con l'area romagnola

An experimental study on relationship between LED lamp characteristics and non image-forming

The general aim of the experimental study, presented in this paper, was that to investigate the relationship between the characteristics of five different types of LED (Light Emitting Diode) lamps, which are nowadays those allowing the highest energy consumption reduction, and the humans non image-forming (NIF) reaction

Sulla sincronizzazione delle misure wireless di scariche parziali con il segnale di tensione a 50 Hz

L\u2019articolo descrive i vari aspetti dei sistemi di misura wireless delle scariche parziali (PD). In particolare, sul problema della sincronizzazione dell\u2019angolo di fase della tensione per il rilevamento e la classificazione delle PD

The Broglio experiment in reproducing “Italian mixed products”

The paper presents the experimental replica of the local traditional and Aegean-derivative pottery at the site of Broglio near Trebisacce (CS, ITA

Il popolamento durante l’età dei metalli

Nell'Alta Valtiberina toscana le prime atte-stazioni della presenza umana risalgono al Paleolitico medio (120.000-100.000 anni fa), ben documentato nei numerosi giaci-menti situati soprattutto sugli antichi terrazzi fluviali del Tevere e della Sovara delle colline di Anghiari. Il popolamento della valle vera e propria, tuttavia, è il risultato di una frequentazione molto più recente che ha inizio durante la fine dell’ultima glaciazione (circa 12.000 anni fa) e perdura più o meno ininterrottamente fino ai giorni nostri. Nella piana del Tevere e lungo i suoi affluenti sono stati individuati i resti di abitati neolitici, dell’età del Rame, dell’età del Bronzo, e dell’età del Ferro, molti dei quali sono stati indagati stratigraficamente e hanno fornito informazioni basilari per ricostruire i modi di vita delle antiche popolazioni nelle diverse fasi cronologiche